Yu-Kyong Kim (Yu Kyong Kim)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 11

Top Topics

Anti Inflammatory Drugs

Preterm Infants

Top Venues

Translational and clinical pharmacology

Drug design, development and therapy

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Hyun Chul Kim, Eunsol Yang, Mu Seong Ban, Yu-Kyong Kim, Sung Hee Hong, Jin-A Jung, In-Jin Jang, Seung Hwan Lee
Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects. Drug design, development and therapy 17 (2023)
Yu-Jeong Son, Min-Kyu Park, Hyeon-Jeong Park, Ha-Yeon Kim, Ye-Lim Jang, Young-Sim Choi, Jun-Gi Hwang, Ji-Hyung Seo, Yu-Kyong Kim
Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects. Pharmaceutics 15 (4) (2023)
Yu-Jeong Son, Min-Kyu Park, Hyeon-Jeong Park, Ha-Yeon Kim, Ye-Lim Jang, Young-Sim Choi, Jun-Gi Hwang, Ji-Hyung Seo, Yu-Kyong Kim
Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects. Pharmaceutics 15 (4) (2023)
Yu-Jeong Son, Min-Kyu Park, Hyeon-Jeong Park, Ha-Yeon Kim, Ye-Lim Jang, Young-Sim Choi, Jun-Gi Hwang, Ji-Hyung Seo, Yu-Kyong Kim
Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects. Pharmaceutics 15 (4) (2023)
Jun Gi Hwang, Sae Im Jeong, Yu-Kyong Kim, Yujin Lee, Sang Chun Ji, Seung Hwan Lee, Min-Kyu Park
Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Translational and clinical pharmacology 30 (4) (2022)
Jun Gi Hwang, Sae Im Jeong, Yu-Kyong Kim, Yujin Lee, Sang Chun Ji, Seung Hwan Lee, Min-Kyu Park
Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Translational and clinical pharmacology 30 (4) (2022)
Yu-Kyong Kim, Jun Gi Hwang, Min-Kyu Park
No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects. Drug design, development and therapy 15 (2021)
Jun Gi Hwang, Yu-Kyong Kim, Young-Sim Choi, Soon Kil Kwon, Joung-Ho Han, Min Kyu Park
Influence of Renal Function on the Single-Dose Pharmacokinetics of Besifovir, a Novel Antiviral Agent for theTreatment of Hepatitis B Virus Infection. Journal of clinical pharmacology (2021)
Inseung Jeon, Yu-Kyong Kim, Ildae Song, Deok Yong Yoon, Ki Young Huh, Xuanyou Jin, Kyung-Sang Yu, Seung Hwan Lee, Yuji Kumagai, In-Jin Jang
The necessary conduct: Exploratory multiregional clinical trials in East Asia. Clinical and translational science 14 (6) (2021)
Mu Seong Ban, Yu-Kyong Kim, Byungwook Kim, Jina Jung, Yong-Il Kim, Jaeseong Oh, Kyung-Sang Yu
Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers. Translational and clinical pharmacology 28 (4) (2020)
Yu-Kyong Kim, Juyoung Lee, Jaeseong Oh, Su-Jin Rhee, Seung Han Shin, Seo Hyun Yoon, SeungHwan Lee, Han-Suk Kim, Kyung-Sang Yu
Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis. Antimicrobial agents and chemotherapy 63 (6) (2019)